StockMacro
Menu

GRAIL

$99.25 +44% in 6 monthsMarket cap $4.5B

GRAL on XNAS, Health Care, GRAIL, Inc., job postings

Measures activity, not value. Not investment advice.

Shares fell 25% in a month as short interest hits 18% and 12-month losses reach $406M.

  • GoodForeign specialist hire applications up 86% over 12 months: 39 vs 21
  • GoodRevenue up 17% over last 12 months to $166.6M

Written by AI from the data on this page, 22 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.

Industry
Services-medical laboratories (Health Care)
Employees
910
Website
grail.com
Listed
Nasdaq, US
Last results
4 Nov 2026
Next results
expected around 11 Jan 2027 (an estimate: a year ago it reported on 12 Jan 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $37.5M, net loss $103.6M.
Quarter to 31 Mar 2023: revenue –, net income -$193.7MQuarter to 2 Apr 2023: revenue –, net income -$193.7MQuarter to 30 Jun 2023: revenue $22.4M, net income -$193.0MQuarter to 30 Jun 2023: revenue $22.4M, net income -$193.0MQuarter to 2 Jul 2023: revenue –, net income -$193.0MQuarter to 1 Oct 2023: revenue $20.7M, net income -$891.4MQuarter to 1 Oct 2023: revenue $20.7M, net income -$891.4MQuarter to 31 Dec 2023: revenue $30.3M, net income -$187.5MQuarter to 31 Dec 2023: revenue $30.3M, net income -$187.5MQuarter to 31 Mar 2024: revenue $26.7M, net income -$218.9MQuarter to 31 Mar 2024: revenue $26.7M, net income -$218.9MQuarter to 30 Jun 2024: revenue $32.0M, net income -$1.6BQuarter to 30 Jun 2024: revenue $32.0M, net income -$1.6BQuarter to 30 Sep 2024: revenue $28.7M, net income -$125.7MQuarter to 30 Sep 2024: revenue $28.7M, net income -$125.7MQuarter to 31 Dec 2024: revenue $38.3M, net income -$97.1MQuarter to 31 Dec 2024: revenue $38.3M, net income -$97.1MQuarter to 31 Mar 2025: revenue $31.8M, net income -$106.2MQuarter to 31 Mar 2025: revenue $31.8M, net income -$106.2MQuarter to 30 Jun 2025: revenue $35.5M, net income -$114.0MQuarter to 30 Jun 2025: revenue $35.5M, net income -$114.0MQuarter to 30 Sep 2025: revenue $36.2M, net income -$89.0MQuarter to 30 Sep 2025: revenue $36.2M, net income -$89.0MQuarter to 31 Dec 2025: revenue $43.6M, net income -$99.2MQuarter to 31 Dec 2025: revenue $43.6M, net income -$99.2MQuarter to 31 Mar 2026: revenue $40.8M, net income -$93.2MQuarter to 31 Mar 2026: revenue $40.8M, net income -$93.2MQuarter to 30 Jun 2026: revenue $44.7M, net income -$110.2MQuarter to 30 Jun 2026: revenue $44.7M, net income -$110.2MQuarter to 30 Sep 2026: revenue $37.5M, net income -$103.6MQuarter to 30 Sep 2026: revenue $37.5M, net income -$103.6M
31 Mar 2023RevenueNet incomeNet losstallest bar $1.6B30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$37.5M-$103.6M
30 Jun 2026$44.7M-$110.2M
31 Mar 2026$40.8M-$93.2M
31 Dec 2025$43.6M-$99.2M
30 Sep 2025$36.2M-$89.0M
30 Jun 2025$35.5M-$114.0M
31 Mar 2025$31.8M-$106.2M
31 Dec 2024$38.3M-$97.1M
30 Sep 2024$28.7M-$125.7M
30 Jun 2024$32.0M-$1.6B
31 Mar 2024$26.7M-$218.9M
31 Dec 2023$30.3M-$187.5M
1 Oct 2023$20.7M-$891.4M
2 Jul 2023–-$193.0M
30 Jun 2023$22.4M-$193.0M
2 Apr 2023–-$193.7M
31 Mar 2023–-$193.7M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $166.6M $141.8M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +17% +17%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$406.2M -$406.2M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$9.44 -$10.67
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. – – 33.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -347% -405% -8.2%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -244% -286% -5.9%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -17.3% -10.1%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. – -$329.8M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $788.7M $540.1M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $0 $0
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). -$788.7M (net cash) -$540.1M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 0.0 0.16
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $54.57
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 29.1
P/SPrice to sales: market cap divided by revenue of the last 12 months. 26.8 3.6
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 22.1 2.6
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 1.8 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
GRAILGRAL (this company) $4.5Bloss26.8+17%-244%
BillionToOneBLLN $4.3B87.09.8+72%11.3%
Caris Life SciencesCAI $5.0B52.54.8+61%9.2%
CareDxCDNA $3.7B28.67.4+39%25.9%
RadNetRDNT $5.5Bloss2.3+21%-0.9%
CelcuityCELC $2.6Bloss–––

Insider Buy/Sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

-$15.2M

bought $0, sold $15.2M

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+20%

442 13F filers vs 368

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

85%

38.1M shares held by 13F filers (30 Sep 2026) of 45.0M outstanding (2 Nov 2026)

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

18%

8.0M shares sold short (30 Oct 2026) of 45.0M outstanding (2 Nov 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

8.7

8.0M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

-2.1%

8.2M shares sold short in the report before, 8.0M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

74%

74% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 66%

Open jobs Job postings open on the company's own careers site today, where we track it. Blank when we do not track this company's careers site yet.

–

We do not track this company's careers site yet.

Open jobs change How the number of open job postings changed over the last 30 days: total hiring demand, any job, any country. Shown only once we have tracked the company for 30 days.

–

We do not track this company's careers site yet.

Employees Total staff the company reported in its latest annual report (10-K), with the change from the year before when both years are reported.

–

No headcount in its annual reports in our data.

Visa hiring (foreign workers) Applications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.

+86%

39 vs 21 applications

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+3.7%

$37.5M vs $36.2M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

–

No data for this company

Federal contracts Money the US government committed to the company in contracts and grants over the last 12 months.

–

No data for this company

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$2.9M

4 quarters, $

Layoff notices Workers named in state WARN layoff notices over the last 12 months (employers must file them 60 days before a large layoff).

–

No data for this company

News (7d) Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

39

39 articles in the last 7 days; its usual week has 6 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

6.5×

39 articles in the last 7 days; its usual week has 6.

Price $99.25 on 20 Nov 2026, +16% over 12 months (12-month range $43.03 to $158.92)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $38.3M in the last 12 months (the 12 months before: -$112.3M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 39 published in the last 12 months, +86% on the 12 months before.
Revenue per quarter. Revenue $37.5M in the latest quarter, +3.7% on a year earlier.
Capital spending per quarter. Capital spending $432K in the latest quarter, +17% on a year earlier.
Institutional holders (13F filers). 442 13F filers reported holding it in the latest 13F quarter, +36% on a year earlier.
Lobbying spend. Lobbying spend: $2.9M published in the last 12 months, -39% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
1 Jun 20268-K and other filingsDirector or officer change
1 Jun 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 Jan 2026Lobbying filinglobbying engagement terminated (ALEXANDER J. BECKLES, L.L.C.)
7 Nov 20258-K and other filingsPrivate placement of securities (Form D)
15 Jul 2025Lobbying filingnew lobbying registration (B HALL STRATEGIES, LLC)
5 Jun 2025Lobbying filinglobbying engagement terminated (BGR GOVERNMENT AFFAIRS)
16 May 20258-K and other filingsDirector or officer change
16 May 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
24 Mar 2025Lobbying filingnew lobbying registration (MARSHALL & POPP, LLC)
22 Oct 20248-K and other filingsDirector or officer change
22 Oct 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
3 Oct 2024Lobbying filingnew lobbying registration (THE HARPLE GROUP, LLC)
15 Aug 2024Lobbying filinglobbying engagement terminated (THE MATHIS HARPLE GROUP)
27 Jun 20248-K and other filingsAsset write-down (impairment)
24 Jun 20248-K and other filingsDirector or officer change
11 Jun 20248-K and other filingsDirector or officer change
11 Jun 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Mar 2024Lobbying filingnew lobbying registration (TIBER CREEK HEALTH STRATEGIES, INC.)
23 Feb 2024Lobbying filinglobbying engagement terminated (TODD STRATEGY GROUP)
21 Dec 2023Lobbying filingnew lobbying registration (BGR GOVERNMENT AFFAIRS)
20 Dec 2023Lobbying filingnew lobbying registration (WILLIAMS AND JENSEN, PLLC)
21 Feb 2023Sharp changeLobbying spend jump: lobbying spend jump, 1.5M vs usual 900K (2022-12-31); 1.7x the same period a year earlier
19 Feb 2023Lobbying filinglobbying engagement terminated (AVOQ, LLC)
Insider net buying (open market)
Month from 1 Aug 2024: -$1.5M published
Month from 1 Oct 2024: -$706K published
Month from 1 Nov 2024: -$427K published
Month from 1 Mar 2025: -$445K published
Month from 1 May 2025: -$6.2M published
Month from 1 Jun 2025: -$410K published
Month from 1 Jul 2025: -$17.6M published
Month from 1 Aug 2025: -$163K published
Month from 1 Oct 2025: -$7.4M published
Month from 1 Nov 2025: -$80.0M published
Month from 1 Dec 2025: -$7.6M published
Month from 1 Mar 2026: -$4.0M published
Month from 1 Apr 2026: -$11.5M published
Month from 1 Jun 2026: -$91K published
Month from 1 Sep 2026: -$7.5M published
Month from 1 Oct 2026: -$7.3M published
Month from 1 Nov 2026: -$323K published
H-1B/E-3 applications certified
Quarter from 1 Jan 2022: 4 published
Quarter from 1 Apr 2022: 16 published
Quarter from 1 Jul 2022: 13 published
Quarter from 1 Oct 2022: 9 published
Quarter from 1 Jan 2023: 4 published
Quarter from 1 Apr 2023: 1 published
Quarter from 1 Jul 2023: 10 published
Quarter from 1 Oct 2023: 6 published
Quarter from 1 Jan 2024: 5 published
Quarter from 1 Apr 2024: 7 published
Quarter from 1 Jul 2024: 9 published
Quarter from 1 Oct 2024: 3 published
Quarter from 1 Jan 2025: 3 published
Quarter from 1 Apr 2025: 11 published
Quarter from 1 Jul 2025: 7 published
Quarter from 1 Jan 2026: 2 published
Quarter from 1 Apr 2026: 4 published
Quarter from 1 Jul 2026: 9 published
Quarter from 1 Oct 2026: 24 published
Revenue per quarter
Quarter ended 30 Jun 2023: $22.4M; public on 14 Aug 2024
Quarter ended 1 Oct 2023: $20.7M; public on 14 Nov 2024
Quarter ended 31 Dec 2023: $30.3M; public on 13 Mar 2026
Quarter ended 31 Mar 2024: $26.7M; public on 15 May 2025
Quarter ended 30 Jun 2024: $32.0M, +43% on a year earlier; public on 14 Aug 2024
Quarter ended 30 Sep 2024: $28.7M, +38% on a year earlier; public on 14 Nov 2024
Quarter ended 31 Dec 2024: $38.3M, +26% on a year earlier; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $31.8M, +19% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $35.5M, +11% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $36.2M, +26% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $43.6M, +14% on a year earlier; public on 13 Mar 2026
Quarter ended 31 Mar 2026: $40.8M, +28% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $44.7M, +26% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $37.5M, +3.7% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Mar 2024: $2.5M; public on 15 May 2025
Quarter ended 30 Jun 2024: $1.4M; public on 14 Aug 2025
Quarter ended 30 Sep 2024: $971K; public on 14 Nov 2025
Quarter ended 31 Dec 2024: $303K; public on 6 Mar 2025
Quarter ended 31 Mar 2025: $62K, -98% on a year earlier; public on 15 May 2025
Quarter ended 30 Jun 2025: $369K, -73% on a year earlier; public on 14 Aug 2025
Quarter ended 30 Sep 2025: $384K, -60% on a year earlier; public on 14 Nov 2025
Quarter ended 31 Dec 2025: $94K, -69% on a year earlier; public on 13 Mar 2026
Quarter ended 31 Mar 2026: $503K, +711% on a year earlier; public on 8 May 2026
Quarter ended 30 Jun 2026: $432K, +17% on a year earlier; public on 7 Aug 2026
Institutional holders (13F filers)
30 Jun 2024 report: 346; public on 14 Aug 2024
30 Sep 2024 report: 286; public on 14 Nov 2024
31 Dec 2024 report: 312; public on 14 Feb 2025
31 Mar 2025 report: 299; public on 15 May 2025
30 Jun 2025 report: 328; public on 14 Aug 2025
30 Sep 2025 report: 326; public on 14 Nov 2025
31 Dec 2025 report: 396; public on 17 Feb 2026
31 Mar 2026 report: 357; public on 15 May 2026
30 Jun 2026 report: 368; public on 14 Aug 2026
30 Sep 2026 report: 442; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $890K published
Quarter from 1 Apr 2022: $960K published
Quarter from 1 Jul 2022: $1.2M published
Quarter from 1 Oct 2022: $1.1M published
Quarter from 1 Jan 2023: $1.5M published
Quarter from 1 Apr 2023: $850K published
Quarter from 1 Jul 2023: $1.0M published
Quarter from 1 Oct 2023: $940K published
Quarter from 1 Jan 2024: $1.1M published
Quarter from 1 Apr 2024: $1.4M published
Quarter from 1 Jul 2024: $1.1M published
Quarter from 1 Oct 2024: $1.1M published
Quarter from 1 Jan 2025: $1.3M published
Quarter from 1 Apr 2025: $1.1M published
Quarter from 1 Jul 2025: $1.1M published
Quarter from 1 Oct 2025: $1.2M published
Quarter from 1 Jan 2026: $1.1M published
Quarter from 1 Apr 2026: $480K published
Quarter from 1 Jul 2026: $460K published
Quarter from 1 Oct 2026: $860K published

What is unusual now

  • Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is lobbying spend reported (quarter) at $860K (30 Sep 2026), 23% below its normal reading of $1.1M; higher than 37% of its own history.
  • Insider net buying (open market): Insiders sold a net $38.3M in the last 12 months (the 12 months before: -$112.3M).
  • H-1B/E-3 applications certified: H-1B/E-3 applications certified: 39 published in the last 12 months, +86% on the 12 months before.
  • Revenue per quarter: Revenue $37.5M in the latest quarter, +3.7% on a year earlier.

Latest records

The names and amounts behind the totals, newest first

Insider trades

All 50 insider trades

Last 90 days: 8 sales, $15.2M; no purchases. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
16 Nov 2026Aaron FreidinChief Financial OfficerSellplanned in advance (10b5-1)3,000$107.62$323KForm 4
16 Oct 2026Joshua J. OfmanChief Executive OfficerSellplanned in advance (10b5-1)20,000$136.85$2.7MForm 4
7 Oct 2026Andrew John PartridgeChief Growth OfficerSell7,873$146.39$1.2MForm 4
7 Oct 2026Aaron FreidinChief Financial OfficerSell23,619$146.39$3.5MForm 4
23 Sep 2026Aaron FreidinChief Financial OfficerSellplanned in advance (10b5-1)4,100$93.34$383KForm 4
23 Sep 2026Joshua J. OfmanChief Executive OfficerSellplanned in advance (10b5-1); after exercising options61,452$97.74$6.0MForm 4
31 Aug 2026Joshua J. OfmanChief Executive OfficerSellplanned in advance (10b5-1)5,000$85.02$425KForm 4
31 Aug 2026Aaron FreidinChief Financial OfficerSellplanned in advance (10b5-1)7,900$85.01$672KForm 4

442 institutions reported shares at the end of Q3 2026, 85% of the shares outstanding; 102 opened a position, 35 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
Farallon Capital Management, L.L.C.4.1M9.05%$570.2M-92K-2.2%
Baker Bros. Advisors LP4.0M8.96%$564.5MNo change
BlackRock, Inc.3.8M8.52%$536.8M+254K+7.1%
Primecap Management Co2.2M4.94%$311.2M+41K+1.9%
State Street Corp2.0M4.48%$282.4M-370K-16%
Vanguard Capital Management LLC1.8M4.10%$258.5M+204K+12%
Morgan Stanley1.2M2.75%$173.1M-227K-16%
Geode Capital Management, LLC1.1M2.48%$156.5M+125K+13%
Deep Track Capital, LP1.1M2.46%$154.7M-731K-40%
Bank of America Corp754K1.68%$105.6M+30K+4.2%

Company events

All 16 company events

In 12 months: 1 director or officer change. Results releases and routine reports are left out.

FiledWhat happenedSource
1 Jun 2026Director or officer change8-K
7 Nov 2025Private placement of securities (Form D)$325.0M sold of $325.0M offeredD
20 Oct 2025Signed a major agreementSame filing: sold shares privately8-K
16 Oct 2025Signed a major agreementSame filing: sold shares privately8-K
17 Sep 2025Signed a major agreementSame filing: took on new debt8-K
16 May 2025Director or officer change8-K
22 Oct 2024Director or officer change8-K
27 Jun 2024Asset write-down (impairment)8-K

Reported lobbying spend: $860K in Q3 2026, $460K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
31 Dec 2025EndedAlexander J. Beckles, L.L.C.for Grail, IncOncology and multi-cancer early detection, including diagnostics and screening; H.R.842 - The Nancy Gardner Sewell Multi-Cancer Early Detection Screening Coverage Act.; Medicare issues as they relate to oncology and multi-cancer early detection, including diagnostics and screening; H.R. 842 - The Nancy Gardner Sewell Multi-Cancer Early Detection Screening Coverage Act.Health issues, Medicare/MedicaidFiling
1 May 2025EndedBGR Government Affairsfor Grail, LLCNot statedFiling
1 Apr 2025NewB Hall Strategies, LLCfor Tiber Creek Health Strategies, Inc. On Behalf Of Grail, LLCIssues related to multi-cancer early detection screening.Medicare/MedicaidFiling
10 Mar 2025NewMarshall & Popp, LLCfor Grail, Inc.Issues related to cancer screening.Health issues, Medicare/Medicaid, Taxation, BudgetFiling
18 Jul 2024NewThe Harple Group, LLCfor Grail, Inc.Issues related to oncology and early multi-cancer detection, including diagnostics and screening.Health issuesFiling
30 Jun 2024EndedThe Mathis Harple Groupfor Grail, IncNot statedFiling
1 Feb 2024NewTiber Creek Health Strategies, Inc.for Grail, LLCIssues related to Medicare and cancer screening.Medicare/MedicaidFiling
24 Jan 2024EndedTodd Strategy Groupfor Grail, Inc.Issues related to oncology and multi cancer early detection, including diagnostics and screening. H.R.2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.Health issuesFiling
Timeline
Kind of data

Timeline

Changes and notable records, by the date each became public

  1. 1 Jun 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  2. 1 Jun 2026Filings record

    Director or officer change

  3. 21 Jan 2026Lobbying record

    GRAIL, INC: lobbying engagement terminated (ALEXANDER J. BECKLES, L.L.C.) (dated 31 Dec 2025)

  4. 7 Nov 2025Filings record

    Private placement of securities (Form D)

  5. 15 Jul 2025Lobbying record

    TIBER CREEK HEALTH STRATEGIES, INC. ON BEHALF OF GRAIL, LLC: new lobbying registration (B HALL STRATEGIES, LLC) (dated 1 Apr 2025)

  6. 5 Jun 2025Lobbying record

    GRAIL, LLC: lobbying engagement terminated (BGR GOVERNMENT AFFAIRS) (dated 1 May 2025)

  7. 16 May 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  8. 16 May 2025Filings record

    Director or officer change

  9. 24 Mar 2025Lobbying record

    GRAIL, INC.: new lobbying registration (MARSHALL & POPP, LLC) (dated 10 Mar 2025)

  10. 22 Oct 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  11. 22 Oct 2024Filings record

    Director or officer change

  12. 11 Oct 2024Insiders record

    DING CHUN R (ten percent owner) bought 78,829 shares of GRAL ($1.0M) (dated 10 Oct 2024)

  13. 3 Oct 2024Lobbying record

    GRAIL, INC.: new lobbying registration (THE HARPLE GROUP, LLC) (dated 18 Jul 2024)

  14. 15 Aug 2024Lobbying record

    GRAIL, INC: lobbying engagement terminated (THE MATHIS HARPLE GROUP) (dated 30 Jun 2024)

  15. 27 Jun 2024Filings record

    Asset write-down (impairment)

  16. 24 Jun 2024Filings record

    Director or officer change

  17. 11 Jun 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  18. 11 Jun 2024Filings record

    Director or officer change

  19. 14 Mar 2024Lobbying record

    GRAIL, LLC: new lobbying registration (TIBER CREEK HEALTH STRATEGIES, INC.) (dated 1 Feb 2024)

  20. 23 Feb 2024Lobbying record

    GRAIL, INC.: lobbying engagement terminated (TODD STRATEGY GROUP) (dated 24 Jan 2024)

  21. 21 Dec 2023Lobbying record

    GRAIL, LLC: new lobbying registration (BGR GOVERNMENT AFFAIRS) (dated 1 Dec 2023)

  22. 20 Dec 2023Lobbying record

    GRAIL, LLC: new lobbying registration (WILLIAMS AND JENSEN, PLLC) (dated 1 Dec 2023)

  23. 19 Feb 2023Lobbying record

    GRAIL: lobbying engagement terminated (AVOQ, LLC) (dated 31 Dec 2022)

  24. 20 Jan 2023Lobbying change

    reported $1.5M of lobbying spend for the quarter ended 31 Dec 2022, 1.7× the same quarter last year.

    Same quarter last year: $890K; its normal quarter is $900K.

    See the evidence
    This period
    $1.5M (the quarter ended 31 Dec 2022)
    Normal quarter (median of 8 earlier)
    $900K
    Typical spread (median absolute deviation)
    $75K
    How far from its usual level
    +5.3
    Same quarter last year
    $890K
    History used
    1,005 days
    2020-12-31: $680K2021-03-31: $810K2021-06-30: $910K2021-09-30: $840K2021-12-31: $890K2022-03-31: $960K2022-06-30: $1.2M2022-09-30: $1.1M2022-12-31: $1.5M
    the quarter ended 31 Dec 20228 earlier quartersnormal: $900K

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least $100K.

    Check it at the source: Senate/House lobbying disclosures (LDA).

  25. 22 Nov 2021Lobbying record

    GRAIL, INC.: new lobbying registration (BALLARD SPAHR LLP) (dated 15 Oct 2021)

  26. 15 Apr 2021Lobbying record

    GRAIL: new lobbying registration (AVOQ, LLC) (dated 1 Mar 2021)

  27. 12 Jan 2021Lobbying record

    GRAIL, INC.: new lobbying registration (GRANT PARK STRATEGIES) (dated 18 Dec 2020)

  28. 17 Sep 2020Filings record

    Registered new securities for sale (S-1)

  29. 9 Sep 2020Filings record

    Registered new securities for sale (S-1)

  30. 25 May 2020Lobbying record

    GRAIL, INC: new lobbying registration (THE MATHIS HARPLE GROUP) (dated 1 Apr 2020)

  31. 29 Apr 2020Lobbying record

    GRAIL, INC.: new lobbying registration (AVENUE SOLUTIONS) (dated 1 Apr 2020)

  32. 27 Apr 2020Lobbying record

    GRAIL, INC.: new lobbying registration (THE MCMANUS GROUP) (dated 1 Apr 2020)

  33. 24 Apr 2020Lobbying record

    GRAIL, INC.: new lobbying registration (TODD STRATEGY GROUP) (dated 20 Apr 2020)

  34. 23 Apr 2020Lobbying record

    GRAIL, INC.: new lobbying registration (FORBES-TATE)

  35. 18 Apr 2020Lobbying record

    GRAIL, INC: new lobbying registration (ALEXANDER J. BECKLES, L.L.C.) (dated 15 Apr 2020)

  36. 16 Apr 2020Lobbying record

    GRAIL LLC: new lobbying registration (MILLER STRATEGIES, LLC) (dated 13 Apr 2020)

  37. 21 Jan 2020Lobbying change

    registered for federal lobbying for the first time in our data (In-House).

    See the evidence (1 source record)
    Source coverage starts
    5 Jan 2011
    Earlier events of other kinds
    0

    "First" means first in our data: it fires only when the source's history began at least 365 days earlier.

  38. 21 Jan 2020Lobbying record

    GRAIL, INC. (FORMERLY GRAIL, LLC): new lobbying registration (in-house) (dated 24 Aug 2021)

  39. 12 Dec 2019Filings record

    Private placement of securities (Form D)

  40. 25 May 2018Filings record

    Private placement of securities (Form D)

Showing the newest 40 of 41 entries; narrow the window or the kind of data to see older ones.

Not listed: 80 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001699031
Ticker
GRAL
Domain
grail.com
Employer name
GRAIL, INC. (1 unverified)
Hq location
CA|SUNNYVALE|94086 (1 unverified)
Lobbying client
grail, grail inc formerly grail, tiber creek health strategies inc on behalf of grail
Name
GRAIL, Inc.
Wikidata
Q104875961
Wikipedia
Grail, Inc.
  • DOL H-1B labor condition applications and PERM certifications508 data points28 Oct 2019 to 31 Aug 2026
  • Federal lobbying disclosures (LDA)22 records, 81 data points31 Mar 2020 to 30 Sep 2026
  • SEC Form 13F institutional holdings90 data points30 Jun 2024 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)43 records13 Mar 2017 to 5 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)211 data points3 Jan 2022 to 2 Nov 2026
  • SEC Form 4 insider transactions50 records, 108 data points22 Aug 2024 to 16 Nov 2026
  • FINRA short interest (twice monthly)171 data points28 Jun 2024 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)1210 data points25 Jun 2024 to 20 Nov 2026
  • Wikipedia pageviews77 data points6 Sep 2026 to 21 Nov 2026